Literature DB >> 23625281

Expression of estrogen receptors (α, β), cyclooxygenase-2 and aromatase in normal endometrium and endometrioid cancer of uterus.

P Knapp1, A Chabowski, A Błachnio-Zabielska, M Walentowicz-Sadłecka, M Grabiec, P A Knapp.   

Abstract

PURPOSE: Endometrial cancer (EC) is one of the most common malignancies of the female genital tract, but the etiology, especially its metabolism is still investigated. The aim of this study was to evaluate the presence and relative expression of Estrogen Receptors (α, β), Cyclooxygenase-2 and Aromatase in both endometrial cancer and normal mucosa. MATERIAL/
METHODS: Two groups of women were selected for the study: 1) patients with endometrioid endometrial cancer (FIGO I; G1 - G3) (n=35) and 2) subjects with normal endometrial tissue (control group, n=29). The expression of Estrogen Receptors (ERα, β), Cyclooxygenase-2 (COX-2), Aromatase were estimated by Western blot analysis. Furthermore, the associations between FIGO classification (stage: Ia, Ib), tumor grade (G) and expression of ERα, β, COX-2, aromatase proteins were evaluated. Overall and disease-free survival curves were generated according to the Kaplan-Meier method. Median follow-up time of the patients examined in this study was 39 months.
RESULTS: The relative expression of each examined protein was markedly higher in the endometrial cancer tissue as compared to the healthy endometrium. The trends towards greater expression along with a tumor progression was noticed (FIGO stage: Ia vs. Ib). Analysis of endometrial cancer risk factors and their influence on survival curves showed only an inverse significant correlations between obesity (BMI: 36.2; n=21) and disease-free survival in EC group (p=0.00872), but there was no significant association between obesity and overall survival (p=0.358).
CONCLUSIONS: Endometrioid endometrial cancer shows relatively higher expression of either ER, COX-2 and aromatase comparing to healthy mucosa, suggesting their involvement in tumor development and progression.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23625281     DOI: 10.2478/v10039-012-0055-1

Source DB:  PubMed          Journal:  Adv Med Sci        ISSN: 1896-1126            Impact factor:   3.287


  5 in total

Review 1.  Intracrine Regulation of Estrogen and Other Sex Steroid Levels in Endometrium and Non-gynecological Tissues; Pathology, Physiology, and Drug Discovery.

Authors:  Gonda Konings; Linda Brentjens; Bert Delvoux; Tero Linnanen; Karlijn Cornel; Pasi Koskimies; Marlies Bongers; Roy Kruitwagen; Sofia Xanthoulea; Andrea Romano
Journal:  Front Pharmacol       Date:  2018-09-19       Impact factor: 5.810

Review 2.  The significance of markers in the diagnosis of endometrial cancer.

Authors:  Monika M Żyła; Jacek R Wilczyński; Marta Kostrzewa; Kinga Księżakowska-Łakoma; Marek Nowak; Grzegorz Stachowiak; Krzysztof Szyłło; Tomasz Stetkiewicz
Journal:  Prz Menopauzalny       Date:  2016-11-15

3.  Altered expression of ERs, aromatase, and COX2 connected to estrogen action in type 1 endometrial cancer biology.

Authors:  Katarzyna Jarzabek; Mariusz Koda; Malgorzata Walentowicz-Sadlecka; Marek Grabiec; Piotr Laudanski; Slawomir Wolczynski
Journal:  Tumour Biol       Date:  2013-07-20

4.  Differential expression of upstream stimulatory factor (USF) 2 variants in eutopic endometria from women with endometriosis: estradiol regulation.

Authors:  Jazmin Castro; Germán Araya; Pamela Inostroza; Paulina Hidalgo; Reinaldo González-Ramos; Hugo Sovino; M Angélica Boric; Ariel Fuentes; M Cecilia Johnson
Journal:  Biol Res       Date:  2015-10-09       Impact factor: 5.612

5.  Dual expression of immunoreactive estrogen receptor β and p53 is a potential predictor of regional lymph node metastasis and postoperative recurrence in endometrial endometrioid carcinoma.

Authors:  Takeshi Obata; Mitsuhiro Nakamura; Yasunari Mizumoto; Takashi Iizuka; Masanori Ono; Jumpei Terakawa; Takiko Daikoku; Hiroshi Fujiwara
Journal:  PLoS One       Date:  2017-11-30       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.